white → orange2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Desoxypipradrol
2-diphenylmethylpiperidine
2-DPMP, Ivory Wave, Purple Wave, VanillaSky, Pippy
Desoxypipradrol is a benzylpiperidine-based stimulant structurally related to methylphenidate and pipradrol.citation needed Developed by Ciba in the 1950s for conditions such as narcolepsy and ADHD, it was ultimately abandoned in favor of methylphenidate. It acts as a norepinephrine-dopamine reuptake inhibitor12 and is distinguished by its exceptionally long duration of action, a consequence of its high lipophilicity which renders it resistant to metabolic breakdown.citation needed It resurfaced as a recreational substance in the late 2000s.3
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~0.25 mg
Light0.25-1.5 mg
Moderate1.5-3.5 mg
Strong3.5-5 mg
Heavy5+ mg
Dosage effects tend to not be linear and effects tend to plateau, while duration progressively increases.
Duration
Onset20-60 minutes
Come Up2-6 hours
Peak6-30 hours
Offset6-40 hours
After Effects1-72 hours
Total10-72 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Desoxypipradrol produces a relatively standard stimulant experience, euphoria, energy, alertness, and heightened sociability, set apart from comparable drugs by its extreme duration. Effects typically persist for at least 24 hours and frequently up to 48, with overdoses producing symptoms lasting three to four days or longer. Its high potency and history of mislabeled sale contribute to elevated rates of adverse reactions, including anxiety, chest pain, tachycardia, and prolonged agitation that has in severe cases lasted up to five days and required physical restraint.
Physical
The body load is that of a potent, exceptionally long-acting stimulant: wakefulness, decreased appetite, sweating, teeth grinding, and a racing heart. Chest pain and myoclonic muscle spasms or twitches have been reported at relatively high rates.
Stimulation
Stimulation is pronounced and exceptionally long-lasting, routinely spanning one to two days from a single dose.
Uncomfortable
Cognitive
The headspace is energetic and talkative, with mood lift and increased sociability giving way at higher exposures to anxiety, moodiness, aggressiveness, and paranoia. Prolonged agitation is a hallmark of its adverse presentations.
Emotional
Positive mood effects can shift into irritability, anxiety, and paranoia, particularly as use extends across its very long duration.
Social
Visual
Auditory
Pharmacology
Pharmacodynamics
Desoxypipradrol acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking the reuptake of both dopamine and norepinephrine at their respective transporters.1 It may also promote dopamine release in certain brain regions. It is notable for its exceptionally high potency relative to structurally related piperidines such as pipradrol and methylphenidate.
Pharmacokinetics
Desoxypipradrol is a highly lipophilic molecule that lacks the polar functional groups typically targeted by metabolic enzymes unlike other substances such as methylphenidate, which possesses an easily cleaved methyl-ester moiety. This confers an extremely long elimination half-life compared to most stimulants. Desoxypipradrol is metabolised by hydroxylation followed by dehydrogynation followed by hydroxylation and hydroxylation followed by ring opening and oxidisation.citation needed
Metabolitesnone documented yet
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Acute tolerance to many effects develops with prolonged repeated use. Users may continue taking the substance across consecutive days for long stretches, but doing so can require progressively larger doses to produce comparable effects.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance
Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
HighHigh abuse potential with significant risk of psychological dependence. Compulsive redosing is commonly reported due to the subtle nature of stimulation, leading users to consume dangerous amounts. Addiction develops at a higher rate than with most other stimulants.
Physical
LowPhysical dependence can develop with chronic use. Cravings and withdrawal effects including anxiety, depression, cognitive fatigue, and irritability may occur upon cessation.
Toxicity
Central Nervous System
Chronic abuse or overdose can cause prolonged neurotoxic effects including severe agitation lasting up to 5 days and myoclonus; long-term heavy use may lead to persistent dopamine receptor downregulation.
Cardiovascular
Chest pain and tachycardia have been reported at relatively high rates; however, overall cardiovascular stimulation at typical doses may be milder than with many other stimulants.
Psychosis Risk
Desoxypipradrol triggers psychosis at a significantly higher rate than other stimulants, with an uncommonly low threshold. Both chronic abuse and single-exposure overdose can induce psychotic states. Symptoms include auditory and visual hallucinations, paranoid delusions, mania, grandiosity, severe confusion, increased aggression, and urges toward self-harm. Psychotic episodes may persist for up to 5 days after drug use.
History & Culture
Development and Initial Research
Desoxypipradrol was developed by the pharmaceutical company Ciba (now Novartis) during the 1950s.4 The compound was initially investigated for therapeutic applications including the treatment of narcolepsy and attention deficit hyperactivity disorder, and…
Legality
By Country
Illegal4
ChinaIllegalState Council, Regulations on the Administration of Narcotic Drugs and Psychotropic Substances (current consolidated text, revised 2024-12-06), Arts. 3 and 4; Ministry of Public Security, National Health Commission and National Medical Products Administration, Catalogue of Non-medical Narcotic Drugs and Psychotropic Substances (2025 edition), as displayed in the current 2026-07-01-updated national directory.5678
Classification began in October 2015. Entry 105 (2-二苯甲基哌啶 / 2-Diphenylmethylpiperidine / CAS 519-74-4 / 2-DPMP) is listed in the 2025 Catalogue of Non-medical Narcotic Drugs and Psychotropic Substances, displayed in the current national directory updated through 2026-07-01. Under current Article 4, ordinary production, operation, use, storage and transport are prohibited, subject to regulated experimental-research provisions. The former supplemental catalogue was repealed and consolidated in 2025. This classification applies nationwide in China.
GermanyIllegalBetäubungsmittelgesetz (BtMG), §§ 1, 3 and 29, and Anlage II (zu § 1 Abs. 1); Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 1 Abs. 2 Nr. 1.91011121314
Desoxypipradrol (2-DPMP), 2-(Diphenylmethyl)piperidin is expressly listed in BtMG Anlage II. Anlage II is the regulated marketable-but-not-prescribable category, but BtMG § 1 makes it a Betäubungsmittel, § 3 requires the applicable BfArM permit for the listed traffic routes, and § 29 criminalizes unauthorized handling and possession without a written acquisition permit. Ordinary unlicensed possession and handling are prohibited, while statutory authorization pathways and the limited § 29 Abs. 5 small-quantity own-use discretion remain. NpSG is expressly inapplicable to BtMG narcotics.
RussiaIllegalGovernment of the Russian Federation Resolution No. 681 of 30 June 1998, current consolidated List I as amended through 11 June 2025; Federal Law No. 3-FZ of 8 January 1998, Article 14.15161718
Under the current official Russian consolidated schedule, the exact parent name (Пиперидин-2-ил)дифенилметан is listed in List I, whose heading states that circulation in the Russian Federation is prohibited. This nationwide List I prohibition provides no product-specific prescription or medical exception beyond the statutory List I purposes.
United KingdomIllegalMisuse of Drugs Act 1971, s. 2(1)(b)-(c) and Schedule 2 Part II para. 1(ac) (latest revised text and current changes through 2025-01-15); Misuse of Drugs Regulations 2001, Schedule 1 para. 1(o) (latest revised text up to 2026-08-28); Misuse of Drugs Regulations (Northern Ireland) 2002, Schedule 1 para. 1(o) as inserted by S.R. 2012/213.232425262728293031
Desoxypipradrol (2-DPMP) is covered by the generic pipradrol-related structural provision in Class B Part II of the Misuse of Drugs Act 1971 and Schedule 1 of the GB and Northern Ireland misuse-of-drugs regulations, effective 13 June 2012. The current Home Office list explicitly gives Class B and Schedule 1. Section 3 supplies the operative import/export rule with its licence exceptions. Separate Schedule 3 treatment of pipradrol esters and ethers does not alter desoxypipradrol's Schedule 1 classification.
Controlled / restricted1
United StatesRestrictedFederal Controlled Substances Act, 21 U.S.C. §§ 802(32), 813, 841, 844 and 952; 21 C.F.R. §§ 1308.11 and 1308.14 (April 1, 2025 edition); DEA Diversion Control Division Controlled Substance Schedules and August 2026 Controlled Substances Alphabetical Order; Texas Health and Safety Code §§ 481.103(a) and 481.116; 16.19.20.65(C)(14) NMAC; Alabama Administrative Code r. 420-7-2-A Appendix, Schedule I; and Ohio Administrative Code r. 4729:9-1-01.32333435363738394041424344454647
Desoxypipradrol does not appear in the current DEA materials, although DEA states that its lists are not comprehensive. Texas, New Mexico, Alabama, and Ohio control the exact compound under different state categories. Pipradrol is Schedule IV under 21 C.F.R. § 1308.14(f)(10), while 21 U.S.C. § 802(32)(A) defines an analogue by reference to Schedule I or II substances and § 813 applies Schedule I treatment only to a qualifying analogue intended for human consumption. No current written federal determination applies those criteria to desoxypipradrol. Import is subject to 21 U.S.C. § 952 if the substance is treated as a covered Schedule I or II substance. NIH PubChem identifies desoxypipradrol as 2-diphenylmethylpiperidine (2-benzhydrylpiperidine; desoxypipradrol; 2-DPMP; CAS 519-74-4; CID 160506; C18H21N). The DEA controlled-substance reference and the 2025 federal Schedule I regulation do not show an exact desoxypipradrol or 2-DPMP entry, although DEA states that its lists are not comprehensive and that an unlisted substance may be treated as a controlled-substance analogue. The Federal Register contains no scheduling document for desoxypipradrol, 2-DPMP, or CAS 519-74-4. Texas controls the compound in Penalty Group 2, and New Mexico, Alabama, and Ohio control it in Schedule I.
Not scheduled1
SwitzerlandNot scheduledVerordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI), SR 812.121.11, current consolidated version dated 13 March 2026, Articles 1 and 2 and Annexes 1–6 (lists a–e).19202122
Current binding Swiss law is the BetmVV-EDI, SR 812.121.11, consolidated as at 13 March 2026. Its Articles 1–2 make Annexes 1–6 the operative controlled-substance lists (a–e). The current Annexes 1–6 contain no entry for Desoxypipradrol, 2-DPMP, 2-(Diphenylmethyl)piperidine or Pipradrol, and the generic Annex 6 classes do not match this scaffold. Diphenylprolinol (D2PM) item 58 is a distinct substance; its listing does not establish control of desoxypipradrol. The absence of a listing concerns controlled-substance scheduling only.
References
Source Pages
Citations
- Simmler LD, Rickli A, Schramm Y, Hoener MC, & Liechti ME. (2014). Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochemical Pharmacology, 88(2), 237-244. https://doi.org/10.1016/j.bcp.2014.01.0241234
- Loi B, Sahai MA, De Luca MA, Shiref H, & Opacka-Juffry J. (2020). The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS)—Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP). Frontiers in Pharmacology, 11, 806. https://doi.org/10.3389/fphar.2020.008061
- Corkery JM, Elliott S, Schifano F, Corazza O, & Ghodse AH. (2012). 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39(2), 253-258. https://doi.org/10.1016/j.pnpbp.2012.05.0211
- Advisory Council on the Misuse of Drugs. (2011-09-13). Consideration of Desoxypipradrol (2-DPMP) and related pipradrol compounds. UK Home Office. https://assets.publishing.service.gov.uk/media/5a7b06a340f0b66eab99e69f/desoxypipradrol-report.pdf1
- 我国管制毒品目录（2026年7月更新，540种+三大类）. ga.sz.gov.cn (n.d.). https://ga.sz.gov.cn/SZJDZX/SZBMFW/content/post_12898420.html1
- 麻醉药品和精神药品管理条例 (国家行政法规库 current consolidated text). xzfg.moj.gov.cn (n.d.). https://xzfg.moj.gov.cn/mobile/law/detail?LawID=17441
- 三部门联合发布最新版《非药用类麻醉药品和精神药品目录》. btgaj.xjbt.gov.cn (n.d.). https://btgaj.xjbt.gov.cn/c/2025-07-28/8428464.shtml1
- 非药用类麻醉药品和精神药品列管办法. gaj.panjin.gov.cn (n.d.). https://gaj.panjin.gov.cn/2015_10/08_00/content-235605.html1
- BtMG - Gesetz über den Verkehr mit Betäubungsmitteln. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/BJNR106810981.html1
- Anlage II BtMG - verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
30 August 2026
Lyrea · Reworded 7 words in Dosage & Duration › Routes 2 › Notes
Lyrea · Reworded 9 words in Pharmacology › Pharmacokinetics
Lyrea · Reworded 2 words in History & Culture › Sections 2 › Content
Lyrea · Reworded 3 words in Dosage & Duration › Routes 2 › Notes
Lyrea · Added a citation in Pharmacology › Pharmacokinetics
Lyrea · Added a source: In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry
Lyrea · Reworded 4 words in Pharmacology › Pharmacokinetics
Lyrea · Reworded 10 words in Pharmacology › Pharmacokinetics
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Desoxypipradrol article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.